231 related articles for article (PubMed ID: 33054114)
21. Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
Perusini MA; Andrews C; Atenafu EG; Gupta V; Maze D; Schuh AC; Yee KW; Bankar A; Davidson MB; Richard-Carpentier G; Chan SM; Sibai J; Schimmer AD; Minden MD; Sibai H
Hematology; 2024 Dec; 29(1):2329027. PubMed ID: 38526239
[TBL] [Abstract][Full Text] [Related]
22. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
23. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
24. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
25. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
26. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
[TBL] [Abstract][Full Text] [Related]
27. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
Hunault-Berger M; Leguay T; Huguet F; Leprêtre S; Deconinck E; Ojeda-Uribe M; Bonmati C; Escoffre-Barbe M; Bories P; Himberlin C; Chevallier P; Rousselot P; Reman O; Boulland ML; Lissandre S; Turlure P; Bouscary D; Sanhes L; Legrand O; Lafage-Pochitaloff M; Béné MC; Liens D; Godfrin Y; Ifrah N; Dombret H;
Am J Hematol; 2015 Sep; 90(9):811-8. PubMed ID: 26094614
[TBL] [Abstract][Full Text] [Related]
28. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
[TBL] [Abstract][Full Text] [Related]
29. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
[TBL] [Abstract][Full Text] [Related]
30. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
31. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
32. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
33. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
34. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
35. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.
Huguet F; Leguay T; Raffoux E; Thomas X; Beldjord K; Delabesse E; Chevallier P; Buzyn A; Delannoy A; Chalandon Y; Vernant JP; Lafage-Pochitaloff M; Chassevent A; Lhéritier V; Macintyre E; Béné MC; Ifrah N; Dombret H
J Clin Oncol; 2009 Feb; 27(6):911-8. PubMed ID: 19124805
[TBL] [Abstract][Full Text] [Related]
36. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R; Chiaretti S; Della Starza I; Spinelli O; Santoro A; Paoloni F; Messina M; Elia L; De Propris MS; Scattolin AM; Audisio E; Marbello L; Borlenghi E; Zappasodi P; Mauro E; Martinelli G; Mattei D; Fracchiolla N; Bocchia M; De Fabritiis P; Bonifacio M; Candoni A; Cassibba V; Di Bartolomeo P; Latte G; Trappolini S; Guarini A; Vitale A; Fazi P; Piciocchi A; Rambaldi A; Foà R
Blood Adv; 2023 Aug; 7(16):4448-4461. PubMed ID: 37276451
[TBL] [Abstract][Full Text] [Related]
37. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
[TBL] [Abstract][Full Text] [Related]
38. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
40. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
